Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial

Fig. 2

Efficacy endpoints of modified intent-to-treat (mITT) and per protocol (PP) population. The BP group is not inferior to the EP group with regards to the response rate (between group difference 13.1 %, 90 % two-sided confidence interval -0.3 to 26.5, meeting the predefined non-inferiority criterion of -15.0 %) in mITT population. The response of the BP group was superior in PP population

Back to article page